Response of subpopulations of the FSall C fibrosarcoma to low dose x-rays and various potential enhancing agents.
The effectiveness of various oxygen carrying treatments in sensitizing subpopulations of the FSallC fibrosarcoma to low doses of radiation was assessed, and compared with survivals obtained with the same cells after in vivo irradiation under normally oxygenated or hypoxic conditions. FSallC tumors were treated with 2-10 Gray then the Hoechst 33342 dye diffusion method was used to separate the tumor into bright (enriched in normally oxygenated cells) and dim (enriched in hypoxic cells) subpopulations. There was good agreement between the survival of normally oxygenated cells in culture and bright cells from tumors and between hypoxic cells in culture and dim cells from tumors over a radiation dosage range of 2-5 Gray. At 10 Gray bright cells from tumors were minimally less sensitive to the radiation dose than normally oxygenated cells in vivo. When maximally effective doses of perfluorochemical emulsions (F44E at 4 g PFC/kg or Fluosol-DA at 2.4 g PFC/kg) or a purified bovine hemoglobin solution (PBHS at 1.32 g protein/kg) were administered 1 hr. prior to radiation therapy with carbogen (95% O2, 5% CO2) breathing prior to and during radiation delivery, low single doses of x-ray (2-5 Gray) were measurably more cytotoxic toward both FSallC tumor cell subpopulations. These results indicate that perfluorochemical emulsions or purified bovine hemoglobin preparations along with carbogen breathing may be able to increase tumor radiosensitivity to the relatively low radiation doses per fraction used in the clinic.
Tanaka
J
J
Dana-Farber Cancer Institute, Boston, MA 02115.
Holden
S A
SA
Herman
T S
TS
Teicher
B A
BA
D000818:Animals; D001562:Benzimidazoles; D015687:Cell Hypoxia; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects / Q000528:radiation effects; D004307:Dose-Response Relationship, Radiation; D004338:Drug Combinations; D004655:Emulsions; D005354:Fibrosarcoma / Q000473:pathology / Q000532:radiotherapy*; D005456:Fluorescent Dyes; D005466:Fluorocarbons / Q000627:therapeutic use*; D006454:Hemoglobins / Q000627:therapeutic use*; D006895:Hydroxyethyl Starch Derivatives; D051379:Mice; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use*; D012513:Sarcoma, Experimental / Q000473:pathology / Q000532:radiotherapy*; D014965:X-Rays
D001562:Benzimidazoles; D004338:Drug Combinations; D004655:Emulsions; D005456:Fluorescent Dyes; D005466:Fluorocarbons; D006454:Hemoglobins; D006895:Hydroxyethyl Starch Derivatives; D011838:Radiation-Sensitizing Agents; C017323:glucose, glycerol, hydroxyethyl starch, perfluorodecalin, perfluorotripropylamine, pluronic F-68, salts, yolk phospholipids drug combination; C017807:bisbenzimide ethoxide trihydrochloride